NEW YORK (GenomeWeb) – Thermo Fisher Scientific and Biocept have signed a non-binding memorandum of understanding to collaborate commercially, Biocept said today.

The companies initially plan to validate Thermo Fisher's Oncomine next-generation sequencing liquid biopsy panels in Biocept's CLIA-certified laboratory.

Following that and other requirements, Thermo Fisher intends to designate Biocept as a Center of Excellence for oncology liquid biopsy initiatives and to pursue commercial opportunities with the company.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.